Fournier's Gangrene as a Possible Side Effect of Bevacizumab Therapy for Resected Colorectal Cancer

被引：19

作者：

Gamboa, Eric O. ^{[1
]}

Rehmus, Esther H. ^{[2
,3
]}

Haller, Nairmeen ^{[3
,4
]}

机构：

[1] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Med, Div Hematol Oncol,Coll Phys & Surg, New York, NY 10019 USA

[2] Akron Gen Med Ctr, Dept Med, Hematol Oncol Sect, Akron, OH USA

[3] Northeastern Ohio Univ Coll Med & Pharm, Rootstown, OH 44272 USA

[4] Akron Gen Med Ctr, Dept Med, Gen Internal Med Sect, Akron, OH USA

来源：

CLINICAL COLORECTAL CANCER | 2010年 / 9卷 / 01期

关键词：

Arterial thromboembolism; FGSIS; Vascular endothelial growth factor; Wound-healing complications; FLUOROURACIL; LEUCOVORIN;

D O I：

10.3816/CCC.2010.n.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing vascular endothelial growth factor. Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism. We present a case of a 67-year-old man who developed Fournier's gangrene during treatment with bevacizumab 4 months after completing mFOLFOX6 (5-FU/leucovorin/oxaliplatin) for CRC. Other than bevacizumab, the patient had no medications and had no medical conditions that would predispose to Fournier's gangrene.

引用

页码：55 / 60

页数：6

共 15 条

[1] Fournier's gangrene: A retrospective clinical study on forty-one patients [J].